Skip to content

Stigmasterol Ameliorates Pulmonary Hypertension by Suppressing the CCL5/CCR5 Signaling Pathway: Taurocholic Acid as a Downstream Mediator.

Oct 2026 · European Journal of Pharmacology · pp. 179492 · 0 citations · 44 references
Medicine

Abstract

Background

Pulmonary hypertension (PH) is a devastating disease characterized by irreversible pulmonary vascular remodeling (PVR), ultimately culminating in right ventricular failure and death. Although previous studies have demonstrated that stigmasterol (STG) reduces cholesterol levels and prevents cardiovascular diseases, its potential role in PH remains unknown. In this study, we investigated the therapeutic effects of STG on SU5416/hypoxia (Su/Hx)-induced PH in mice and elucidated the underlying molecular mechanisms.

Methods

Through bioinformatics analysis and network pharmacology, we identified STG as a promising herbal compound for PH treatment. Both in vitro and in vivo experiments validated that STG ameliorates platelet-derived growth factor-BB (PDGF-BB)-induced proliferation and migration of pulmonary artery smooth muscle cells (PASMCs), as well as PVR and right ventricular hypertrophy (RVH). Molecular dynamics (MD) simulation, MM-PBSA calculation, and microscale thermophoresis (MST) were used to validate direct STG-CCL5 binding. Functional rescue experiments with taurocholic acid (TCA) were also performed.

Results

Molecular docking, MD simulation, and MST revealed spontaneous direct binding between CCL5 and STG, with an MST-derived KD of 4.72 μM. While CCL5 promoted PDGF-BB-induced PASMC proliferation and migration, CCR5 inhibition counteracted these effects. STG ameliorated PASMC proliferation and migration by modulating CCL5. Furthermore, metabolomics and mass spectrometry analyses showed decreased taurocholic acid levels in lung tissues of CCR5-knockout (CCR5-/-) mice in the Su/Hx model. TCA reversed the protective effects of STG on PASMC proliferation and migration, supporting TCA as a downstream functional mediator.

Conclusion

In conclusion, our study demonstrates that STG ameliorates Su/Hx-induced PH by modulating the CCL5/CCR5 signaling pathway, with taurocholic acid acting as a downstream mediator. Further investigations are warranted to explore the clinical applicability of STG-based therapies for PH patients.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.